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        Asthma is a complex infl  ammatory syndrome 
that aff  ects   >  10% of the North American popu-
lation. The worldwide prevalence, morbidity, 
and mortality of asthma have signifi  cantly in-
creased over the last three decades (  1  ). Asthma is 
a chronic infl  ammatory disease of the small air-
ways that is characterized by mast cell, eosino-
phil, and mononuclear cell infi  ltration of the 
submucosa along with goblet cell hyperplasia. 
The infl  ammatory response in asthma is tightly 
associated with airway hyperresponsiveness to 
antigen-specifi  c and nonspecifi  c stimuli (  2  ). 
In humans, and in a mouse model, CD4  +   Th2 
cells play a crucial role in orchestrating airway 
infl  ammation by producing IL4, IL5, and IL13 
and by regulating the production of IgE and the 
growth and diff  erentiation of mast cells and eo-
sinophils (  3, 4  ). Although the role of cytokines 
in the asthmatic response is relatively well un-
derstood, little is known about the transcriptional 
regulation of these mediators in asthma (  5, 6  ). 
  The transcription factor (TF) NF-    B regu-
lates many facets of the infl  ammatory response 
and also appears (  7, 8  ) to have a role in the patho-
genesis of asthma. For example, activated NF-
    B has been identifi  ed in the airways of patients 
with asthma, and agents that exacerbate asthma 
such as allergens, ozone, and viral infections also 
stimulate NF-    B (  9  ). Furthermore, corticoste-
roids, the fi  rst-line treatment for asthma, are 
potent inhibitors of NF-    B activation (  10  ). Fi-
nally, mice that are null for the p50 or c-Rel 
subunits of NF-    B develop signifi  cantly less air-
way infl  ammation after allergen challenge (  11  ). 
We recently identifi  ed activating TF 3 (ATF3) 
as a potent negative regulator of the infl  amma-
tory response in macrophages (  12  ), where it an-
tagonized NF-    B  –  induced responses. ATF3 is 
a member of the CREB family of BZip (basic 
leucine zipper) transcription factors (  13  ). Its role 
in dampening infl  ammation and its capacity to 
antagonize NF-    B  –  induced responses prompted 
us to examine its role in a mouse model of hu-
man asthma (  12  ). 
    RESULTS   
  ATF3 is induced in a mouse asthma model 
  OVA sensitization and challenge led to a sig-
nifi  cant increase in ATF3 transcription in the 
lungs of WT mice (  Fig. 1 A  ), and this was par-
alleled by increased expression of the protein 
(  Fig. 1 B  ).   Immunohistochemical localization 
showed weak ATF3 staining in the epithelium 
of saline-treated WT mice. Upon treatment 
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1.00   ±   0.24; and ATF3-OVA, 1.19   ±   0.34). Airway resis-
tance was signifi  cantly increased in the OVA-treated ATF3-
null mice when compared with their WT counterparts (  Fig. 
2 A  ).   The increased airway resistance in ATF3-null mice was 
accompanied by a fi  vefold increase in infl  ammatory cells in 
bronchoalveolar lavage (BAL) fl  uid (  Fig. 2 B  ), whereas there 
was only a twofold increase in the cellular infl  ux in WT BAL 
fl  uid (  Fig. 2 B  ). Diff  erential counts showed a signifi  cantly 
higher number of macrophages, lymphocytes, and eosinophils 
in the BAL fl  uid of ATF3-null mice (  Fig. 2 C  ). Remarkably, 
there was a 4.7-fold increase in pulmonary eosinophils (  Fig. 
2 C  ). Histological analysis of lung tissue from OVA-treated 
WT mice showed an accumulation of eosinophils and mono-
nuclear cells in the peribronchial and perivascular regions and 
edema of the airway interstitium compared with saline con-
trols (  Fig. 2 D  ). Each of these features was markedly increased 
in OVA-treated ATF3-null mice. Signifi  cantly, there was a 
dramatic increase in infl  ammatory cell infi  ltrate in the alve-
olar spaces of ATF3-null mice when compared with WT mice 
(  Fig. 2 D  ). Airway mucus production, as determined by peri-
odic acid-Schiff    staining, was similar between WT and 
ATF3-null mice under baseline conditions. However, goblet 
cell hyperplasia and mucous hypersecretion were more pro-
nounced in allergic ATF3-null mice (  Fig. 2 D  ). 
  Effect of ATF3 defi  ciency on Th2 responses 
  A hallmark of asthma is a skewed Th2-type immune response 
(  4  ). Lungs from OVA-sensitized WT mice demonstrated sig-
nifi  cant increases in the Th2 cytokines IL4, IL5, and IL13 
mRNA compared with saline-treated controls, and this re-
sponse was markedly increased in OVA-treated ATF3-null 
mice (  Fig. 3 A  ).   Signifi  cant levels of secreted IL4, IL5, and IL13 
were found in the BAL fl  uid of OVA-treated WT mice when 
compared with a saline control group, and these levels were 
signifi  cantly increased in the BAL fl  uid of OVA-treated ATF3-
null mice (  Fig. 3 B  ). No signifi  cant change in gene expression 
of the Th1 cytokine IFN-     or the Th1-inducing cytokine 
IL12 was seen in either WT or ATF3-null mice after OVA 
treatment compared with saline controls (unpublished data). 
  Interestingly, there was no signifi  cant diff  erence in the 
levels of OVA-specifi  c IgE and IgG1 between WT and ATF3-
null mice (  Fig. 4, A and B  ).   In contrast, the level of OVA-
specifi  c IgG2a, a serum Ig isoform typical of Th1 responses, 
was dramatically reduced in ATF3-null mice (  Fig. 4 C  ). 
  ATF3 expression in T lymphocytes 
  We determined ATF3 mRNA levels in CD4  +   lymphocytes 
because these cells are the major source of IL4, IL5, and IL13 
(  6  ). Baseline transcription of ATF3 was signifi  cantly higher in 
splenic CD4  +   T cells cultured under Th2 conditions. How-
ever, TCR ligation (anti-CD3/anti-CD28) dramatically in-
creased ATF3 expression under Th0 conditions, whereas it 
was not increased under Th1 conditions (  Fig. 5 A  ).   There-
fore, ATF3 expression in CD4  +   lymphocytes is regulated 
both by the cytokine environment and by TCR ligation, and 
the eff  ect is much more pronounced under Th2 conditions. 
with ovalbumin (OVA), increased levels of ATF3 were seen 
in the infl  ammatory cell infi  ltrate, smooth muscle layer, and 
around blood vessels. Interestingly, ATF3 staining of epithe-
lium remained predominantly cytosolic, whereas infl  amma-
tory cells showed strong nuclear localization (  Fig. 1 C  ). No 
ATF3 was detected in tissue from ATF3-null animals by PCR, 
Western blot, or immunostaining. 
  Role of ATF3 in lung function and allergen-induced 
infl  ammatory responses 
  The role of ATF3 in regulating the asthmatic response was 
explored in OVA-sensitized and -challenged WT and ATF3-
null mice. Lung resistance (R  L  ), as a measure of airway hyper-
reactivity, was assessed using aerosolized methacholine and 
invasive plethysmography. Baseline airway resistance was not 
signifi  cantly diff  erent between WT and ATF3-null mice 
(WT-saline, 1.17   ±   0.05; WT-OVA, 1.36   ±   0.03; ATF3-saline, 
    Figure 1.         Lung ATF3 expression in OVA-induced airway infl  ammation.  
(A) Quantitative real-time PCR analysis of ATF3 mRNA in lung tissue on 
day 29 after sensitization with OVA in WT and ATF3-null mice. (B) Western 
blot analysis for ATF3 protein in lung homogenates from individual animals 
used in A. (C) ATF3 expression in lung tissue of saline- or OVA-treated 
WT mice as determined by immunohistochemical staining with rabbit 
anti  –  mouse ATF3 antibody. Arrowheads, ATF3 staining of infl  ammatory 
cells; arrows, ATF3 staining of smooth muscle cells and epithelium. 
Real-time PCR results are expressed as mean   ±   SEM for six independent 
experiments. *, P   <   0.05 by comparison to saline control. Bars, 25   μ  m.     JEM VOL. 205, September 29, 2008 
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Our ChIP experiments demonstrated that Junb was recruited 
to a site in close apposition to the ATF3 binding site in the 
target promoters (  Fig. 6 B  ), whereas c-Fos, Fos B, Fra-1, and 
Fra-2 were not (not depicted). 
  ATF3 regulates histone acetylation at the IL4, IL5, 
and IL13 promoters 
  TF and cofactors act together to produce sustained gene tran-
scription via modifi  cation to histone structure that enhances 
TF accessibility (  14  ). ATF3 may also be involved in this pro-
cess, as we have previously shown ATF3-related HDAC1 
binding and associated histone deacetylation at H3 and H4 
residues. Such modifi  cations, in the main, are involved with 
transcriptional inhibition. We thus investigated histone acet-
ylation in the IL4, IL5, and IL13 promoters in WT and ATF3-
null CD4  +   lymphocytes. In these studies, naive CD4 cells 
were cultured under Th2 conditions and then processed for 
ChIP. WT cells showed signifi  cant H4 acetylation at the IL4, 
IL5, and IL13 promoters, whereas cells from ATF3-null mice 
showed an increase in histone acetylation at the IL4, IL5, and 
IL13 promoters (  Fig. 6 B  ). 
  ATF3 inhibits Th2 cytokine production in CD4  +   T cells 
  OVA-sensitized CD4  +   T cells from the BAL fl  uid of ATF3-null 
mice had increased capacity to produce IL4, IL5, and IL13 
compared with their WT counterparts (  Fig. 5 B  ). This was 
paralleled by increased cytokine production after OVA pep-
tide stimulation (  Fig. 5 C  ). IL4, IL5, and IL13 secretion was 
also increased as determined by ELISA (unpublished data). 
  ATF3 binds to the IL4, IL5, and IL13 promoters 
in Th2 lymphocytes 
  We used MotifMogul (  12  ) to predict ATF3 binding sites in 
the IL4, IL5, and IL13 promoters and identifi  ed a single site 
with a high degree of confi  dence in each promoter. These 
predictions were validated by chromatin immunoprecipita-
tion (ChIP;   Fig. 6 A  ).   Additional experiments demonstrated 
that treatment of mice with the OVA peptide further in-
creased ATF3 binding to the IL4, IL5, and IL13 promoters in 
CD4  +   lymphocytes (  Fig. 6 A  ). These results indicate that IL4, 
IL5, and IL13 are direct binding targets of ATF3. Multiple 
AP1 and NFAT sites have been identifi  ed in the Th2 cyto-
kine locus and these are thought to coordinate transcription. 
    Figure 2.         Enhanced airway hyperresponsiveness and airway infl  ammation in ATF3-null mice.   (A) Allergen-induced airway hyperresponsiveness 
was assessed in saline-treated and OVA-treated WT (Bl6) or ATF3-null mice by invasive plethysmography on day 29. Data represent the fold increase in 
airway resistance to aerosolized methacholine. Baseline airway resistance was not signifi  cantly different between WT and ATF3-null mice. (B) BAL fl  uid 
was obtained on day 29 from saline-treated and OVA-treated WT (Bl6) and ATF3-null mice, and the total number of cells was determined. (C) Cells were 
stained with Diff-Quik stain and differential counts were obtained. Macro, macrophage; lymph, lymphocyte; neut, neutrophil; eos, eosinophil. Error bars 
show mean   ±   SEM. (D) Lung sections of saline- and OVA-treated WT and ATF3-null mice were stained with hematoxylin and eosin (H  &  E) or periodic acid-
Schiff staining (PAS). Arrows indicate infl  ammatory cells. AW, airways. Bars, 100   μ  m. Results are determined from groups of six mice *, P   <   0.05 by com-
parison to saline; **, P   <   0.05 by comparison to WT.     2352 ATF3 AND AIRWAY INFLAMMATION   | Gilchrist et al. 
  ATF3 is activated in response to allergen challenge in the 
lungs of WT mice and contributes to the regulation of the 
Th2 cytokines IL4, IL5 and IL13, as well as many CCL che-
mokine genes that contribute signifi  cantly to immune cell in-
fl  ux into the lung (  15  ). These increased cytokine levels can 
account for some of the key eff  ects on the asthma phenotype 
seen in these mice. IL13 induces diff  erentiation of goblet cells 
and secretion of mucin in the airways of mice after allergen 
challenge (  18  ). IL4 induces typical Th2 responses, including 
airway goblet cell metaplasia in a mouse asthma model (  19  ). 
IL5 promotes growth and maturation of eosinophil precursors 
and stimulates chemotaxis of mature eosinophils, prolonging 
their survival in allergic infl  ammatory tissue sites by inhibition 
of apoptosis (  20  ). 
  Similar levels of OVA-specifi  c IgE and IgG1 were in-
duced in ATF3-null mice, indicating that they are competent 
in their ability to generate OVA-specifi  c T cell responses and 
  Chemokine gene induction 
  Previous studies identifi  ed chemokines as particularly impor-
tant for cellular infl  ux into the asthmatic lung (  15, 16  ). Con-
sistent with this observation, there was a dramatic increase in 
several CCL chemokines, CCL2, 7, 8, and 11, in the lungs of 
OVA-sensitized/challenged ATF3-null mice when compared 
with their WT counterparts (  Fig. 7 A  ).   CCL11 is the eosino-
phil-specifi  c chemokine, eotaxin 1. In addition, other chemo-
kines, including CXCL1, 2, and 5 are also highly up-regulated 
in the lungs of OVA-treated ATF3-null mice (  Fig. 7 B  ). 
    DISCUSSION   
  ATF3 is a member of the CREB/ATF family of BZip TFs that 
participate in a wide variety of biological phenomena includ-
ing development, memory, and apoptosis (  17  ). We recently 
demonstrated that ATF3 is a negative regulator of TLR4-in-
duced infl  ammation (  12  ), and we show in this paper that it 
signifi  cantly dampens the development of allergic airway in-
fl  ammation. Our observations provide a clear link between se-
vere asthmatic infl  ammation and airway disease with the defect 
in transcriptional control mediated by the TF ATF3. 
    Figure 3.         Enhanced Th2 cytokine production in ATF3-null mice.  
(A) IL4, IL5, and IL13 mRNAs were determined by real-time PCR in whole-
lung tissue from saline- and OVA-treated WT and ATF3-null mice on day 
29. Data are expressed as relative mRNA expression compared with EF1a. 
(B) IL4, IL5, and IL13 protein levels were determined in BAL fl  uid obtained 
on day 29 from saline- and OVA-treated WT and ATF3-null mice. 
*, P   <   0.05 for saline versus OVA in WT and ATF3-null mice. Data 
represent mean   ±   SEM from six different animals.     
    Figure 4.         Humoral responses in ATF3-null mice.   (A – C)  Serum  OVA-
specifi  c IgE, IgG1, and IgG2a were determined by specifi  c ELISAs. *, P   <   
0.05 by comparison to saline; **, P   <   0.05 by comparison to WT. Error bars 
show mean   ±   SEM.     JEM VOL. 205, September 29, 2008 
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cytes and that ATF3 binds to the Th2 cytokine promoters in 
close proximity to the AP-1 family TF, Junb. Junb has previ-
ously been shown to be necessary for the induction of IL4, 
IL5, and IL13 (  23, 24  ). Previous work indicates that ATF3 
can physically interact with many AP-1 family members in-
cluding Junb (  25  ). Thus, in Th2-skewed CD4 lymphocytes, 
ATF3 and Junb function in a feed-forward loop. 
  The selective allergen-induced production of Th2 cyto-
kines and chemokines in association with diminished IFN-     
production is a hallmark of the asthmatic response (  26  ). Th2 
skewing has been mechanistically linked to changes in chro-
matin structure (  6  ). Our previous observations demonstrating 
changes in chromatin structure after regulated binding of ATF3 
and HDAC1 (  12  ) suggest a possible mechanism for Th2 cy-
tokine regulation by this TF. 
  The promoters of IL4 and IL13 share similar cis-regula-
tory elements within 500 bp of the transcription start site 
(TSS) that bind multiple TFs, particularly NFAT and AP-1 
(Junb), which strongly synergize to induce transcription (  27  ). 
undergo Ig isotype switching, although this is not enhanced 
despite increased Th2 cytokine production. It has been pre-
viously shown that IL4, through the induction of the TF STAT6, 
directs the transactivation of the C     and C    1 promoters (  21  ). 
Thus, ATF3 is not absolutely required for IgE and IgG1 ex-
pression, nor does it appear to play a role in dampening IgE 
production. The diminished OVA-specifi  c IgG2a in ATF3-
null mice are interesting, as IFN-     regulation of the transcription 
factor TBX21 (T-bet) in B-lymphocytes controls IgG class 
switching to IgG2a (  22  ). As IFN-     levels were undetectable 
in the BAL of ATF3-null mice (unpublished data), it is possi-
ble that the severe Th2 skewing in the ATF3-null animals 
accounts for this stark phenomenon. However, direct induc-
tion of T-bet transcription by ATF3 cannot be ruled out and 
will require further investigation. 
  We previously identifi  ed ATF3 as a component of NF-
    B  –  containing transcriptional complexes in LPS-triggered 
macrophages. In this study, we show that ATF3 functions in 
AP-1  –  containing complexes in Th2-skewed CD4 lympho-
    Figure 5.         ATF3 expression and Th2 Cytokine regulation in CD4  +   T cells.   (A) ATF3 mRNA expression in CD4  +   lymphocyte cultured under Th1, Th2, or 
Th-neutral conditions. Splenic CD4  +   cells were isolated and cultured in the presence of cytokines plus anti-CD3/anti-CD28 antibodies for 72 h and then 
restimulated with anti-CD3/anti-CD28 antibodies for the indicated times. RNA was isolated and ATF3 mRNA expression determined by real-time PCR. 
(B) IL4, IL5, and IL13 production in CD4  +   lymphocytes from BAL fl  uid was determined by Elispot assay. BAL fl  uid cells from WT and ATF3-null mice treated 
with saline or OVA were incubated in the absence (untreated) or presence of anti-CD3/anti-CD28 antibodies or 500   μ  g/ml OVA peptide. *, P   <   0.05 by 
comparison to saline; **, P   <   0.05 by comparison to WT. Error bars show mean   ±   SEM.     2354 ATF3 AND AIRWAY INFLAMMATION   | Gilchrist et al. 
lung tissue (  32  ). IL13 is known to induce chemokine expression, 
a mechanism that was only partly dependent on STAT6 ex-
pression (  33, 34  ). Macrophages are signifi  cant producers of lung 
chemokines and can respond to IL13 through PPAR receptor 
signaling pathway, which may explain this phenomenon (  35  ). 
Conversely, ATF3 may play a direct regulatory role in control-
ling chemokine expression, as has been previously shown for 
RANTES (  36  ) and CCL4 (  37  ). Like the Th2 cytokine locus, 
CCL and CXCL chemokines are also clustered on mouse chro-
mosomes 11 and 5, respectively (  38  ). Our data showing the en-
hanced up-regulation of these clustered CCL chemokines 
defi  ne a potential mechanism to explain the pronounced in-
fl  ammatory cell infi  ltrate in ATF3-null mice leading to asth-
matic exacerbation. Given the complex interplay between 
diverse cell types, signaling pathways, and cis-regulatory regions 
contributing to the exacerbated chemokine profi  les seen in 
the lungs of ATF3-null mice, elucidation of this mechanism 
will require more in-depth and cell-specifi  c examination. 
  In conclusion, ATF3-null mice generate a complete asthma-
like phenotype, including airway infl  ammation, remodeling, 
and resulting hyperresponsiveness, and a lack of responsive-
ness from the ATF3 pathway confers susceptibility to severe 
allergic disease. 
  MATERIALS AND METHODS 
  Animals.     C57/Bl6 mice were purchased from Charles River Laboratories. 
ATF3      /      mice were a gift from T. Hai (Ohio State University, Columbus, OH). 
These NFAT/AP-1 regions are called P sites and act via co-
operative binding to form a higher order transcriptional com-
plex. We identifi  ed ATF3 recruitment to the essential P2 
region of the IL4 promoter (  28  ). Importantly, Type I HDAC 
(HDAC1, 2, or 3) activity has been identifi  ed in this region 
of the promoter (  29  ). Therefore, ATF3-mediated HDAC1 
recruitment and resulting eff  ects on histone acetylation levels 
off  er a mechanistic explanation for this observation. Signifi  -
cantly less is known about regulatory regions of the IL13 pro-
moter, although the ATF3 binding site is also, amid P sites, 
closely opposed to the TSS (  30  ). These similarities in promoter 
binding site architecture and histone regulation may lead to the 
shared expression kinetics of IL4 and IL13. 
  Transcriptional control of the IL5 promoter is less com-
pletely described. There are four cis elements necessary for full 
transcriptional activation (  31  ). The fi  rst of these, termed IL5A, 
is found     940 bp from the TSS and is within     40 bp of the 
ATF3 binding site. This is the upstream enhancer region of IL5, 
and deletion of these sites inhibits transcription by     50% (  31  ). 
As ATF3 can recruit HDAC activity to these sites, resulting in 
condensed chromatin and inhibited gene transcription, this may 
be a necessary regulatory switch in Th2 cytokine production. 
  A signifi  cant hallmark of asthma is accumulation of eosino-
phils, neutrophils, lymphocytes, and macrophages in the lung, a 
process which is highly dependent on chemokines. This cellular 
infl  ux is directly proportional to disease severity. Many cell 
types contribute to chemokine mRNA profi  les seen in asthmatic 
    Figure 6.         In vivo ATF3 recruitment and histone acetylation in the Th2 cytokine locus.   (A) ChIP analysis of ATF3 to predicted binding sites in the 
IL4, IL5, and IL13 promoters. CD4  +   cells were isolated from BAL fl  uid of WT mice that had been treated with saline (Sal) or OVA. ChIP was performed, as 
outlined in Materials and methods, using rabbit anti-ATF3 antibody. DNA from input or immunoprecipitated (ATF3) fractions was measured by PCR ampli-
fi  cation of specifi  c promoter sequences. Results are pooled chromatin samples representative of three mice. (B) ChIP analysis assessing ATF3 binding, Junb 
binding, and histone H4 acetylation on the IL4, IL5, and IL13 promoters. CD4  +   lymphocytes  purifi  ed from spleens of WT and ATF3-null mice were differen-
tiated for 72 h under Th2 conditions and then left unstimulated (0 h) or stimulated with anti-CD3/anti-CD28 antibodies for 4 h. ChIP was performed as 
outlined in Materials and methods, and quantitative PCR analysis was performed with promoter-specifi  c primers as indicated above each graph. The 
y-axis of each graph represents the level of specifi  c antibody precipitation relative to the total input control for each cell type.     JEM VOL. 205, September 29, 2008 
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  BAL.     The right lung was isolated with a suture and lavaged with one wash 
of 1 ml of saline. The total number of leukocytes per 50-  μ  l aliquot was deter-
mined after methylene blue staining. The remaining BAL fl  uid was centri-
fuged at 200   g   for 5 min at 4  °  C, and supernatants were stored at     80  °  C until 
assay of cytokine protein levels. The remaining cells were cytospun onto glass 
slides. Cell diff  erentials were determined by Diff  -Quik staining (Siemens). 
  Lung histology.     The left lung tissue was fi  xed in 10% neutral buff  ered for-
malin at 20  °  C for 15 h. The tissues were embedded in paraffi   n and cut into 
5-  μ  m sections. A minimum of 10 fi  elds was randomly examined by light mi-
croscopy by a blinded observer. 
  Assay of T lymphocytes.     Spleens were mechanically dissociated in cold 
PBS, followed by depletion of erythrocytes with lysis buff  er containing 
NH  4  Cl. Naive CD4  +   T cells were isolated (either from spleen cells or BAL 
fl  uid) by negative selection with (Miltenyi Biotec). Purity of CD4  +   cell pop-
ulations was   >  98% as determined by fl  ow cytometry. Th cell cultures were 
established as previously described (  40  ). In brief, CD4  +   cells (10  6  /well) were 
plated in RPMI 1640 (Invitrogen) containing 10% FCS, 2 mM L-glutamine, 
100 U/ml penicillin, 100   μ  g/ml streptomycin, 10 mM Hepes (Invitrogen), 
and 20   μ  M 2-ME (Sigma-Aldrich) were incubated at 37  °  C in a 5% CO  2   at-
mosphere and stimulated for 72 h in 10   μ  g/ml of anti  –  mouse CD3  –   and 
10   μ  g/ml of anti  –  mouse CD28  –  coated 24-well plates (BD Biosciences). In 
addition, 10 ng/ml IL4 and 10   μ  g/ml of anti  –  IFN-     antibody (Th2 condi-
tions) or 5 ng/ml IL12 plus 10   μ  g/ml of anti-IL4 (Th1 conditions) or 20   μ  g/ml 
of anti-IL4, 20   μ  g/ml of anti-IL12, and 10   μ  g/ml of anti  –  IFN-     (Th-
neutral [Th0] conditions). After 6 d, T cells were washed in PBS and then 
reseeded on CD3/CD28-coated plates for the times indicated. For OVA-
specifi  c activation, CD4  +   cells were incubated with 500   μ  g/ml OVA 
(Thermo Fisher Scientifi  c) for 5 d. Cytokine analysis for IL4, IL5, and IL13 
were performed by ELISPOT (BD Biosciences), according to the manufac-
turer  ’  s protocol. 
  Real-time PCR analysis.     Total RNA was prepared from lung homoge-
nates using Trizol reagent (Invitrogen) according to the manufacturer  ’  s pro-
tocol. cDNA was produced with MMLV Reverse transcription (Promega), 
according to the manufacturer  ’  s recommendations, and primed with oligo 
d(T) (Promega). Quantitative real-time PCR was performed on an ABI 
7700 (Applied Biosystems) using TaqMan Universal PCR Master Mix (Ap-
plied Biosystems). Commercially available primer/probe pairs (Applied Bio-
systems) were used at a fi  nal concentration of 0.9 mM. The PCR program 
was as follows: 50  °  C for 2 min and 95  °  C for 10 min (95  °  C for 15 s and 60  °  C 
for 1 min) for 40 cycles. All data were normalized to EF1-     expression in the 
same cDNA set. 
  Western blot.     Lung homogenates were dissociated in 500   μ  l RIPA buff  er 
(PBS and 1% NP-40). 10   μ  g of protein from each sample was mixed with 
Laemmli loading buff  er. Samples were separated on a 4  –  20% gradient SDS-
PAGE gel and transferred onto a PVDF membrane (Bio-Rad Laboratories). 
The membrane was then incubated with primary antibodies for 1 h at room 
temperature. The secondary antibody, horseradish peroxidase  –  conjugated 
goat anti  –  rabbit IgG (1/5,000; AbD Serotec) was incubated for 1 h at room 
temperature. Labeling was detected by chemiluminescence by addition of 
SuperSignal substrate solution (Thermo Fisher Scientifi  c). 
  ChIP.     After stimulation, lymphocytes were fi  xed in formaldehyde and ChIP 
assay was performed, as previously described, with rabbit anti-ATF3 anti-
body (C terminus; Santa Cruz Biotechnology, Inc.), Anti-Junb (Santa Cruz 
Biotechnology, Inc.), Anti-c-Fos (Pan; Santa Cruz Biotechnology, Inc.), 
and anti-acetylated histone-H4 (Millipore) (  12  ). Quantitative real-time 
PCR was performed using primers specifi  c for the predicted ATF3 binding 
region of IL4, IL5, and IL13 with TaqMan Universal PCR Master Mix (Applied 
Biosystems) and SYBR green detection. IL4 forward, 5    -GGTCTAGGAT-
GCGAGAAGGT-3    ; and reverse, 5    -GCCTAGCTGCTTCCTGC-
TAT-3    . IL5 forward, 5    -CGAACCTGCTGTGTGTGACA-3    ; and reverse, 
All animal use procedures were approved by the University of Washington 
Animal Care Committee (Seattle, WA). 
  Allergen sensitization and challenge.     Mice were sensitized and later 
challenged with OVA (Thermo Fisher Scientifi  c) as previously described (  39  ). 
All solutions, including OVA, were negative when tested for LPS contami-
nation by the Limulus assay (sensitivity   >  0.01 ng/ml LPS; Sigma-Aldrich). 
Mice were immunized with 100   μ  g OVA complexed with aluminum hy-
droxide in a 0.2-ml volume, administered by i.p. injection on days 0 and 14. 
Mice were anesthetized i.p. with 130 mg/kg ketamine and 8.8 mg/kg xyla-
zine in normal saline before receiving an intranasal dose of 100   μ  g OVA 
(0.05 ml of 2 mg/ml) on day 14 and 50   μ  g OVA (0.05 ml of 1 mg/ml) on 
days 26, 27, and 28. The control group received 0.2 ml of normal saline with 
alum i.p. on days 0 and 14 and 0.05 ml saline without alum intranasally on 
days 14, 26, 27, and 28. 
  Pulmonary function testing.     On day 29, invasive pulmonary mechanics 
were measured in mice in response to methacholine in the same manner as 
previously described (  39  ). The mice, ventilated with a tidal volume of 200   μ  l 
and respiratory rate of 120 breaths per minute using a MiniVent ventilator 
for mice (Harvard Bioscience), received aerosolized solutions of methacho-
line (0, 3.125, 6.25, 12.5, 25, and 50 mg/ml in normal saline) via an AER 
1021 nebulizer aerosol system (Buxco Research Systems) with 2.5  –  4-  μ  m 
particle size generated by NEB0126 nebulizer head (Nektar). A commercial 
plethysmography system (PLY4111 plethysmograph, MAX II amplifi  er and 
pressure transducer system, and Biosystem XA software; Buxco Research Sys-
tems) was used to determine R  L   as calculated from measures of pressure and 
fl  ow and expressed as cm H  2  O/ml/s). 
    Figure 7.         Enhanced chemokine expression in allergic airway hy-
perresponsiveness in ATF3-null mice.   (A and B) CCL (A) and CXCL (B) 
mRNAs were determined by realtime PCR in whole-lung tissue from 
saline- and OVA-treated WT and ATF3-null mice on day 29. Results are 
expressed as relative mRNA compared with EF1a. *, P   <   0.05 by compari-
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5    -TGCTTTGGTGGCTTGGCCTT-3    . IL13 forward, 5   -AGCGGCC  A-
CTGGATTTTCCA-3    ; and reverse, 5    -CTTGTGGCCTT  A  G  C  C  T  G-
TTG-3    . Fold enrichment after real-time PCR was calculated as follows: 
2^   –   (Ct  Ets1  Ct  input  )/2^   –   (Ct  rbIg     –   Ct  input  ). 
  ELISA.     IL4, IL5, and IL13 levels were measured using specifi  c commer-
cially available ELISA assays according to the manufacturer  ’  s protocols (R  &  D 
Systems). OVA-specifi  c IgE and IgG were determined in serum samples col-
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  Statistical analysis.     Data were analyzed using analysis of variance, followed 
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